Join our discussion group "Valuation in Life Sciences"
Categories > Reports
Deal Terms in Alzheimer's Disease 2000 - 2014
In this report 21 Alzheimer deals are analyzed. Not only are the publicly available figures displayed, each deal is analyzed how the not disclosed milestones are distributed, what royalty rates are most likely, and what sales assumptions were used at the time of closing the deal.
Success Rates in Biotech - Going The Wrong Way
The report "Success Rates in Biotech - Going The Wrong Way" summarizes our review of 211 public biotech companies comprising over 1,500 drug development projects
Content and Figures